
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder caused by the expansion of CTG repeats in the 3′ untranslated region of DMPK. Although skeletal muscle and cardiac manifestations are among the most recognized features of the disease, DM1 also affects the central nervous system (CNS) and impacts significantly patients’ quality of life, with manifestations ranging from cognitive and behavioral abnormalities to sleep disturbances and, in the congenital form of the disease (CDM), severe neurodevelopmental impairment.
Yersinia pestis is the etiological agent of pandemic-causing plague with no Food and Drug Administration (FDA) approved vaccines. The natural emergence or intentional release of antimicrobial-resistant strains are alarming, necessitating development of new-generation vaccines and immunization strategies that produce rapid and durable immunity. Herein, we evaluated immediate (within 7 days) or longterm (6 months) protection and immune responses combining patented live-attenuated vaccines (LAVs) with trivalent adenovirus-type 5-based vaccine (Ad5-YFV) C57BL/6 mice. Animals were immunized with either a two dose prime-pull strategy (intramuscular [i.m.] injection LAVs followed by intranasal [i.n.] instillation of Ad5-YFV, 21 days apart) or a 1-dose strategy by simultaneous administration of LAVs (i.m.) and Ad5-YFV (i.n.). Animals immunized with both strategies were either challenged after 6 months or, with the simultaneous strategy, 7 days post-vaccination in lethal pneumonic or bubonic Y. pestis CO92 infection models. Mice immunized with both strategies were completely protected and elicited robust and durable humoral and cellular immune responses through 6 months. Simultaneous vaccination also protected animals against bubonic (100%) and pneumonic (80%) challenges 7 days post-vaccination with rapid induction of immunoglobulin M (IgM), IgG3, and total IgG humoral responses. Thus, these vaccines and strategies are suitable for reactive (emergency) and preventive (in endemic regions) use.